Novo Nordisk A/S (NYSE:NVO) is facing supply limitations for its weight-loss drug, Wegovy, in the U.S. Healthcare firms are trying to convince investors that weight-loss medications won't affect their profits. The efficacy of Wegovy could boost the global obesity drug market to $100 billion within the next decade. However, concerns about the cost of weight-loss medications, uncertainty about their long-term use, and potential lack of insurance coverage could limit their market potential. Eli Lilly And Co (NYSE:LLY) is set to launch its Mounjaro weight-loss drug in the U.S., adding pressure to Novo Nordisk.